Industry

USFDA gives nod to Unichem Laboratories for Divalproex Sodium

These are the generic equivalent of Depakote ER (Divalproex Sodium) extended-release tablets 250 mg and 500 mg, of AbbVie Inc, it added.

The Health Master

March 1, 2022

194

USFDA Drug product Approval — USFDA Approval

Last Updated on December 31, 2023 by The Health Master

New Delhi: Unichem Laboratories Ltd on Monday said it has received approval from the US health regulator to market its generic version of Divalproex Sodium extended-release tablets used for treatment bipolar disorder and migraine.

The approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) of Divalproex Sodium extended-release tablets of strengths 250 mg and 500 mg, Unichem Laboratories Ltd said in a regulatory filing.

Click for more articles on USFDA

These are the generic equivalent of Depakote ER (Divalproex Sodium) extended-release tablets 250 mg and 500 mg, of AbbVie Inc, it added.

The tablets are indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, as monotherapy and adjunctive therapy and prophylaxis of migraine headaches, the company said.

The product will be commercialised from Unichem’s Goa plant, it added.

Must read

USFDA approves this drug for all heart patients to cut death, hospitalization risk

USFDA gives nod to Zydus to market Dapagliflozin tablets

USFDA gives nod to Strides Pharma for Amantadine HCL Softgel Capsules

USFDA gives nod to Lupin for sNDA for Solosec

USFDA gives nod to this Molecule to treat retinal vascular diseases

USFDA authorised Bebtelovimab as antibody drug

Also read

Drug recall: Aurobindo, Sun Pharma recall these products

CDSCO gives nod to Sun Pharma to conduct Phase 4 clinical…

Drug recall: Medical Device – Infusion Pumps recalled due to this reason